Antithrombotic and fibrinolytic drugs for retinal vein occlusion: A systematic review and a call for action

Summary

Optimal management of retinal vein occlusion (RVO) is still a matter of debate. Antithrombotic and fibrinolytic drugs have been investigated after demonstration of a role of thrombosis in the complex pathogenesis of the disease. Aim of our study was to systematically summarise best available evidence on the acute treatment and on the secondary prevention of RVO with antithrombotic and fibrinolytic drugs. A computer-assisted search of the MEDLINE and EMBASE electronic databases up to January 2009 was performed. Two review authors selected all published randomised controlled trials (RCTs) from the search, assessed study quality and extracted data. Based on Jadad’s score, RCTs were stratified into three quality categories. A total of six RCTs were included. Only one RCT of high quality was identified. A total of 384 patients were investigated, 234 with central retinal vein occlusion and 150 with branch retinal vein occlusion. No study enrolled more than 100 patients. Three studies compared therapeutic doses of low-molecular-weight heparin (LMWH) with low-dose aspirin, one study compared ticlopidine with placebo and two studies compared intravenous fibrinolytic therapy followed by warfarin or aspirin with either haemodilution or no treatment. A partial improvement of visual acuity was reported in every study, independently of the study drug. No long-term secondary prevention study was published. The present systematic review suggests that antithrombotic therapy, in particular LMWH, may be part of the therapeutic armamentarium for patients with recent onset RVO. No firm recommendation can be provided given the limited available evidence.

Keywords

Retinal vein occlusion - antithrombotic drugs - low-molecular-weight heparin - thrombolysis

• References

• 1 Klein R, Klein BE, Moss SE. et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133-143.
• 2 Hayreh SS, Zimmerman B, McCarthy MJ. et al. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61-77.
• 3 Koizumi H, Ferrara DC, Bruè C. et al. Central retinal vein occlusion case-control study. Am J Ophthalmol 2007; 144: 858-863.
• 4 Janssen MC, den Heijer M, Cruysberg JR. et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021-1026.
• 5 Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-311.
• 6 Mohamed Q, McIntosh RL, Saw SM. et al. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114: 507-519.
• 7 McIntosh RL, Mohamed Q, Saw SM. et al. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114: 835-854.
• 8 Jadad AR, Moore AR, Carrol D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin Trials 1996; 17: 1-12.
• 9 Kohner EM, Hamilton AM, Bulpitt CJ. et al. Streptokinase in the treatment of central retinal vein occlusion. Trans Ophthal Soc UK 1974; 94: 599-603.
• 10 Kohner EM, Pettit JE, Hamilton AM. et al. Streptokinase in central retinal vein occlusion: a controlled clinical trial. Br Med J 1976; 1: 550-553.
• 11 Houtsmuller AJ, Vermeulen JA, Klompe M. et al. The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984; 15: 219-229.
• 12 Farahvash MS, Moghaddam MM, Moghimi S. et al. Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. Can J Ophthalmol 2008; 43: 79-83.
• 13 Farahvash MS, Farahvash MM, Moradimogadam M. et al. Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion. Arch Iran Med 2008; 11: 539-543.
• 14 Farahvash MS, Moradimogadam M, Farahvash MM. et al. Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. Arch Iran Med 2008; 11: 418-422.
• 15 Ageno W, Cattaneo R, Manfredi E. et al. Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Thromb Res. 2009 Epub ahead of print.
• 16 Hattenbach LO, Friedrich AC, Lerche R. et al. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 2009; 29: 932-940.
• 17 Berker N, Batman C. Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 2008; 86: 245-252.
• 18 Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005; 24: 493-519.
• 19 Vannas S, Raitta C. Anticoagulant treatment of retinal venous occlusion. Am J Ophthalmol 1966; 62: 874-884.
• 20 Vannas S, Orma H. Experience of treating retinal venous occlusion with anticoagulant and antisclerosis therapy. AMA Arch Ophthalmol 1957; 58: 812-828.
• 21 Hecker SP, Zweng HC. Central retinal artery occlusion successfully treated with plasmin. J Am Med Assoc 1961; 176: 1067-1069.
• 22 Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006; 114: 79-102.
• 23 Williamson TH. Central retinal vein occlusion: what’s the story?. Br J Ophthalmol 1997; 81: 698-704.
• 24 Sodi A, Giambene B, Marcucci R. et al. Atherosclerotic and thrombophilic risk factors in patients with recurrent central retinal vein occlusion. Eur J Ophthalmol 2008; 18: 233-238.
• 25 Sofi F, Marcucci R, Bolli P. et al. Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis 2008; 198: 223-227.